Almac
Almac Group, often referred to simply as Almac, is a leading global contract development and manufacturing organisation headquartered in the United States. Established in 2004, Almac has expanded its operational footprint across key regions, including Europe and Asia, solidifying its presence in the pharmaceutical and biotechnology sectors. Specialising in drug development, clinical trial services, and commercial manufacturing, Almac distinguishes itself through its innovative solutions and commitment to quality. The company has achieved significant milestones, including the successful launch of numerous life-saving therapies, positioning itself as a trusted partner for clients in the healthcare industry. With a strong emphasis on customer collaboration and cutting-edge technology, Almac continues to enhance its market position, making a notable impact on the global landscape of drug development and manufacturing.
DitchCarbon Score
How does Almac's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Chemicals industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Almac's score of 36 is higher than 97% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Almac's reported carbon emissions
In 2023, Almac reported total carbon emissions of approximately 133,895,000 kg CO2e, which includes 12,728,000 kg CO2e from Scope 1, 17,434,000 kg CO2e from Scope 2, and 103,733,000 kg CO2e from Scope 3 emissions. This data highlights the company's comprehensive approach to tracking its carbon footprint across all scopes. Almac has set ambitious climate commitments, aiming to reduce its absolute Scope 1 and Scope 2 emissions by 50% by 2030, using 2019 as the baseline year. This commitment reflects a proactive stance in addressing climate change within the pharmaceutical and biotechnology sector. Additionally, Almac has committed to achieving net-zero emissions across all scopes by 2050, aligning with global climate goals. The company is actively working towards these targets, demonstrating its dedication to sustainability and environmental responsibility.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2019 | 2020 | 2021 | 2022 | 2023 | |
|---|---|---|---|---|---|
| Scope 1 | 32,159,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 |
| Scope 2 | 15,404,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 |
| Scope 3 | - | - | - | 00,000,000 | 000,000,000 |
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Almac is committed to some reduction initiatives we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
